Metabolomic and Lipidomic Profiling of Gliomas—A New Direction in Personalized Therapies

Gaca-Tabaszewska, Magdalena; Bogusiewicz, Joanna; Bojko, Barbara

doi:10.3390/cancers14205041

Cited by 12 publications

(4 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When considering individualized therapy for GBM, we often think of novel treatment options, however, as presented in this review, even surgery, radiotherapy, and chemotherapy can be personalized to an extent. In particular, with our better understanding of GBM pathophysiology and more precise classification, in the near future chemotherapeutic agents could be personalized based on molecular and metabolic characteristics of the tumor [ 165 ]. Indeed, precision medicine approaches are likely to play a crucial role in the treatment of GBM.…”

Section: Discussionmentioning

confidence: 99%

Personalized Treatment of Glioblastoma: Current State and Future Perspective

Rončević

Koruga

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most aggressive glial tumor of the central nervous system. Despite intense scientific efforts, patients diagnosed with GBM and treated with the current standard of care have a median survival of only 15 months. Patients are initially treated by a neurosurgeon with the goal of maximal safe resection of the tumor. Obtaining tissue samples during surgery is indispensable for the diagnosis of GBM. Technological improvements, such as navigation systems and intraoperative monitoring, significantly advanced the possibility of safe gross tumor resection. Usually within six weeks after the surgery, concomitant radiotherapy and chemotherapy with temozolomide are initiated. However, current radiotherapy regimens are based on population-level studies and could also be improved. Implementing artificial intelligence in radiotherapy planning might be used to individualize treatment plans. Furthermore, detailed genetic and molecular markers of the tumor could provide patient-tailored immunochemotherapy. In this article, we review current standard of care and possibilities of personalizing these treatments. Additionally, we discuss novel individualized therapeutic options with encouraging results. Due to inherent heterogeneity of GBM, applying patient-tailored treatment could significantly prolong survival of these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Personalized Treatment of Glioblastoma: Current State and Future Perspective

Rončević

Koruga

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…The pursuit of personalized medicine continues, with researchers focusing on targeted therapies that are tailored to the unique attributes of each patient’s condition. Metabolic and lipidomic studies are among the most promising avenues for this endeavor, as they provide granular analyses of alterations in the small molecule composition within a biological system or sample [ 206 ].…”

Section: Proteomics and Metabolomicsmentioning

confidence: 99%

Deciphering Glioblastoma: Fundamental and Novel Insights into the Biology and Therapeutic Strategies of Gliomas

Onciul,

Brehar,

Toader

et al. 2024

CIMB

View full text Add to dashboard Cite

Gliomas constitute a diverse and complex array of tumors within the central nervous system (CNS), characterized by a wide range of prognostic outcomes and responses to therapeutic interventions. This literature review endeavors to conduct a thorough investigation of gliomas, with a particular emphasis on glioblastoma (GBM), beginning with their classification and epidemiological characteristics, evaluating their relative importance within the CNS tumor spectrum. We examine the immunological context of gliomas, unveiling the intricate immune environment and its ramifications for disease progression and therapeutic strategies. Moreover, we accentuate critical developments in understanding tumor behavior, focusing on recent research breakthroughs in treatment responses and the elucidation of cellular signaling pathways. Analyzing the most novel transcriptomic studies, we investigate the variations in gene expression patterns in glioma cells, assessing the prognostic and therapeutic implications of these genetic alterations. Furthermore, the role of epigenetic modifications in the pathogenesis of gliomas is underscored, suggesting that such changes are fundamental to tumor evolution and possible therapeutic advancements. In the end, this comparative oncological analysis situates GBM within the wider context of neoplasms, delineating both distinct and shared characteristics with other types of tumors.

show abstract

“…Secondly, untargeted metabolomic was used to evaluate the changes of cell and cell culture medium (CCM) metabolism caused by anlotinib in the treatment of glioma. Untargeted metabolomic is a method to study the overall changes of small molecule metabolites, which reflects the physiological activities in organisms 12 . This technology has been applied to study the toxic mechanism of external stimuli by measuring the metabolic changes in organisms.…”

Section: Introductionmentioning

confidence: 99%

UHPLC-HRMS-based metabolomic and lipidomic characterization of glioma cells in response to anlotinib

Shi

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Anlotinib, as a promising oral small-molecule antitumor drug, its role in glioma has been only reported in a small number of case reports. Therefore, anlotinib has been considered as a promising candidate in glioma. The aim of this study was to investigate the metabolic network of C6 cells after exposure to anlotinib and to identify anti-glioma mechanism from the perspective of metabolic reprogramming. Firstly, CCK8 method was used to evaluate the effects of anlotinib on cell proliferation and apoptosis. Secondly, ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS)-based metabolomic and lipidomic were developed to characterize the metabolite and lipid changes in cell and cell culture medium (CCM) caused by anlotinib in the treatment of glioma. As a result, anlotinib had concentration-dependent inhibitory effect with the concentration range. In total, twenty-four and twenty-three disturbed metabolites in cell and CCM responsible for the intervention effect of anlotinib were screened and annotated using UHPLC-HRMS. Altogether, seventeen differential lipids in cell were identified between anlotinib exposure and untreated groups. Metabolic pathways, including amino acid metabolism, energy metabolism, ceramide metabolism, and glycerophospholipid metabolism, were modulated by anlotinib in glioma cell. Overall, anlotinib has an effective treatment against the development and progression of glioma, and these remarkable pathways can generate the key molecular events in cells treated with anlotinib. Future research into the mechanisms underlying the metabolic changes is expected to provide new strategies for treating glioma.

show abstract

Metabolomic and Lipidomic Profiling of Gliomas—A New Direction in Personalized Therapies

Cited by 12 publications

References 88 publications

Personalized Treatment of Glioblastoma: Current State and Future Perspective

Personalized Treatment of Glioblastoma: Current State and Future Perspective

Deciphering Glioblastoma: Fundamental and Novel Insights into the Biology and Therapeutic Strategies of Gliomas

UHPLC-HRMS-based metabolomic and lipidomic characterization of glioma cells in response to anlotinib

Contact Info

Product

Resources

About